Tamoxifen in the treatment of recurrent ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 7, Issue 4, 1997, Pages 256-261

  Marth, C ^a   Sorheim N ^b   Kaeern J ^a   Trope C ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Antiestrogen; Ovarian cancer; Palliation; Salvage therapy; Tamoxifen

Indexed keywords

ANTIESTROGEN; CISPLATIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL RATE;

EID: 0030671159     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00463.x     Document Type: Article

References (25)

1. Kristensen GB, Tropé C. Epithelial ovarian carcinoma. Lancet 1997; 349: 113-17.
2. Lazo JS, Schwartz PE, MacLusky NJ, Labaree DC, Eisenfeld AJ. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. Cancer Res 1984; 44: 2266-71.
3. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 1994; 70: 449-52.
4. Myers AM, Moore GE, Major FJ. Advanced ovarian carcinoma: Response to antiestrogen therapy. Cancer 1981; 48: 2368-72.
5. Schwartz PE, Keating G, MacLusky N, Naftolin F, Eisenfeld A. Tamoxifen therapy for advanced epithelial ovarian cancer. Obstet Gynecol 1982; 59: 583-7.
6. Landoni F, Epis A, Gorga G, Regallo M, Vassena L, Mangioni C. Hormonal treatment in advanced epithelial ovarian cancer. In: Pamutti F, eds. Anti-oestrogens in Oncology. Past, Present and Prospects. Amsterdam, New York, Oxford: Excerpta Medica, 1985: 262-5.
7. Shirey DR, Kavanagh JJ, Gershenson DM, Freedman RS, Copeland LJ, Jones LA. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985; 66: 575-8.
8. Slevin ML, Harvey VJ, Osborne RJ, Sheperd JH, Williams CJ, Mead GM. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 1986; 22: 309-12.
9. Weiner SA, Alberts DS, Surwitt EA, Davis J, Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987; 27: 208-13.
10. Belinson JL, McClure M, Badger G. Randomized trial of megestrol acetate vs megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987; 28: 151-5.
11. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996; 62: 4-6.
12. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 1991; 68: 269-72.
13. Osborne RJ, Malik ST, Slevin ML, Harvey VJ, Spona J, Salzer H, Williams CJ. Tamoxifen in refractory ovarian cancer: The use of a loading dose schedule. Br J Cancer 1988; 57: 115-16.
14. Pagel J, Rose C, Thorpe S, Hald I. Treatment of advanced ovarian carcinoma with tamoxifen. A phase II trial. Proc 2nd Eur Conf Clin Oncol 1983; 42 (Abstract).
15. Hammerlynck JVTH, Vermorken JB, Van Der Burg MEL. Phase II study of tamoxifen in advanced ovarian cancer. Proc 3nd Eur Conf Clin Oncol 1985; 43 (Abstract).
16. Campbell JJ, Rome RM, Quinn MA, Pepperrell RJ, Morgan WJ. Tamoxifen for recurrent progressive epithelial ovarian tumours. Proc XI Clin Oncol Soc Australia 1984; 73 (Abstract).
17. Rowland K, Bonomi P, Wilbanks G, Yordan E, Graham J, Dunne C. Hormone receptors in ovarian carcinoma. Proc Amer Soc Clin Oncol 1985; 456 (Abstract).
18. Jakobsen A, Bertelsen K, Sell A. Cyclic hormonal treatment in ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol 1987; 23: 915-16
19. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 1957-68.
20. Jäger W, Sauerbrei W, Beck E, et al. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 1995; 15: 2639-42.
21. Miller AB, Hoostrafien B, Staquet M, Winkler A. Reporting results in cancer treatment. Cancer 1981; 47: 207-14.
22. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, Knapp RC. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.
23. Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995; 56: 175-80.
24. Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Los LN, Tropé CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993; 169: 40-52.
25. Tropé C, Johnsson JE, Sifurdson K. High-dose medroxyprogesterone acetate for the treatment of ovarian carcinoma. Cancer Treat Rep 1982; 66: 1441-3.